Archive for the 'Pulmonary Delivery' Category

03 Jan

Pulmonary Delivery of Beclomethasone Liposome Aerosol in Volunteers (Discussion)

The purpose of this preliminary study was to evaluate the tolerance and safety of Bec-DLPC liposome aerosols for the treatment of asthma and other inflammatory lung diseases employing an aqueous jet nebulizer system. No significant spiro-metric, blood chemical, hematologic, and clinical abnormalities were noted in the 10 volunteers who inhaled Bec-DLPC liposome aerosols and DLPC-only […]

01 Jan

Pulmonary Delivery of Beclomethasone Liposome Aerosol in Volunteers (Results)

Aerosol Dosage The first set of aerosol exposures consisted of inhaling DLPC alone (mouth breathing) for 15 min on day 1. The mean inhaled dose was 14.0±1.8 mg (range, 12.7 to 16.7 mg) during the 15-min exposure (Table 1). Based on body weight, the mean inhaled dose of DLPC was 194±12 jmg/kg/d. The exposure on […]

30 Dec

Pulmonary Delivery of Beclomethasone Liposome Aerosol in Volunteers (Materials and Methods)

Description of Volunteers Normal, nonsmoking subjects (six male, four female) (Table 1) were enrolled after being found qualified by medical examination. Extensive laboratory examinations were performed, including pulmonary function tests, blood chemistry, and hematology studies. Volunteers were admitted overnight following each aerosol exposure to the General Clinical Research Center, The Methodist Hospital, Houston. The protocol […]

28 Dec

Pulmonary Delivery of Beclomethasone Liposome Aerosol in Volunteers (Introduction)

Study objective: To test the tolerance and safety of single doses of beclomethasone dipropionate (Bec)-dilauroylphosphatidylcholine (DLPC) liposome aerosol in volunteers. Design: Single-dose inhalations of liposome preparations of Bec-DLPC and DLPC alone were administered for 15 min from a jet nebulizer (Puritan-Bennett, modified twin jet; mass median aerodynamic diameter of 1.6 |xm) under close clinical and […]

© 2008 HIV/AIDS News & Information